Black Diamond ended the third quarter of 2024 with approximately $112.7 million in cash, cash equivalents and investments which the Company ...

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

On Tuesday, Black Diamond Therapeutics (NASDAQ:BDTX) shares maintained its Buy rating and $11.00 price target from H.C. Wainwright. The biotechnology company, focused on precision... On Monday, TD ...

Black Panther: Eyes of Wakanda just got a gorgeous new logo. The series is a four-part animated anthology taking place in the MCU. With each episode self-contained, it follows different Wakandan ...

On Tuesday, Black Diamond Therapeutics Inc (BDTX) stock saw a decline, ending the day at $2.86 which represents a decrease of $-0.06 or -2.05% from the prior close of $2.92. The stock opened at $2.88 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

1 Day BDTX 0.31% DJIA -0.15% Russell 2K -0.41% Health Care/Life Sciences -1.07% ...

Other study co-investigators include Ken Geles and Elizabeth Buck, at Black Diamond Therapeutics in New York City. This work was supported by National Institutes of Health grant P30CA01608.